Neoadjuvant Anbenitamab Meets Primary Endpoint in Ph 3 HER2-Positive Breast Cancer Trial April 7, 2026
Imfinzi + Imjudo combined with lenvatinib and TACE demonstrated a statistically significant PFS improvement in embolisation-eligible unresectable liver cancer in EMERALD-3 Ph 3 trial April 7, 2026
OS beyond two years for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of Ph 2 THIO-101 trial in NSCLC reported April 7, 2026
Ph 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint of Spleen Volume Reduction but not Abs-TSS March 31, 2026
Updated Ph 2 Data Showing Continued Improvement in Median OS with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer Reported March 31, 2026
Namodenoson Positive Data in Ph 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient Announced March 31, 2026
Positive Topline Results from Ph 2 PANOVA-4 Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer Announced March 31, 2026
ZEGFROVY® (Sunvozertinib) Shows Antitumor Activity in 1L NSCLC Patients with EGFR PACC or Other Uncommon Mutations March 31, 2026
Mature median OS data from ongoing ACCENT clinical trial of narmafotinib + chemo in advanced pancreatic cancer announced March 24, 2026
Positive Ph 3 Results from WU-KONG28 Study of ZEGFROVY® (Sunvozertinib) vs. Chemo in 1L NSCLC with exon20ins Mutation Announced March 24, 2026
Positive Ph 1 expansion data for EpCAM PROBODY® ADC, varsetatug masetecan (Varseta-M) in late-line metastatic CRC announced March 24, 2026
Ph 1a data of TOS-358 in heavily pretreated patients with PI3Kα-mutant metastatic breast cancer and other solid tumors presented March 24, 2026
Data from Ph 1/2 ReDiscover trial of 400mg BID zovegalisib (RLY-2608) + fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer announced March 24, 2026
Extended long-term survival observed in Ph 2a trial in advanced NSCLC treated with aglatimagene besadenovec (aglatimagene or CAN-2409) March 24, 2026
Primary endpoint met in Ph 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile March 24, 2026
TALZENNA Plus XTANDI Significantly Improves Radiographic PFS in Metastatic Prostate Cancer March 24, 2026
First-in-human Erda-iDRS (formerly TAR-210) results in intermediate‑risk NMIBC highlighted March 17, 2026
ProstACT Ph 3 Study (Part 1) of TLX591-Tx Achieves Primary Objectives in PSMA+ve metastatic CRPC Patients March 17, 2026
Results from PIK3CA WT Cohort of Ph 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer Published in Journal of Clinical Oncology March 17, 2026
Zemcelpro® (dorocubicel) positive results in high- and very high-risk blood cancers to be reported March 17, 2026
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% March 17, 2026
